biotech stocks
biotech stocks Articles
Turning a $10,000 investment into $1 million represents a financial dream for many — a 100x return that would require an annualized growth rate of approximately 63% over a decade. This level of...
Published:
Pfizer (NYSE:PFE) is a global pharmaceutical giant that has long been a cornerstone of medical innovation and today boasts a $128 billion market cap. Renowned for its blockbuster drugs like Lipitor...
Published:
If you’re interested in biotechnology stocks, billionaires Julian and Felix Baker are the ones to turn to. According to Forbes, the brothers, each worth an estimated $2.8 billion, run Baker Bros....
Published:
Market pullbacks can make nervous investors leery of investing in industries that are more speculative. Wall Street still has big expectations for Viking Therapeutics.
Published:
Biotech investing is a thrill-a-minute ride. Biotech stocks can take investors soaring to new heights and fabulous wealth opportunities or send them into the pits of despair. The drug discovery...
Published:
The surge in interest investors have displayed for companies delivering weight loss drugs has been impressive. Indeed, the growth various weight loss drugs have seen is notable, with GLP-1 agonists...
Published:
Investors have long sought to maximize gains by timing the market – buying low and selling high. However, success in trading, or investing over relatively short-term time frames, generally requires...
Published:
Biotech stocks are some of my favorite stocks to watch and invest in for a couple of reasons. First, they give you an opportunity to earn a meaningful return while knowing that your investment can...
Published:
Market pullbacks can make nervous investors leery of investing in industries that are more speculative. Wall Street still has big expectations for Vir Biotechnology.
Published:
Investing in biotech stocks can be rewarding. Not just because these stocks have the potential to produce meaningful gains in your portfolio, but also because when you invest in them, you’re...
Published:
With the third quarter in full swing, the bulls have not lost their grip on equities. The market momentum isn’t likely to run out of steam anytime soon, according to UBS strategist Vincent Heaney,...
Published:
With the pandemic largely in the rear-view mirror, COVID-19 vaccine winner Novavax has seen shares fall. Yet, analysts have high hopes for the stock.
Published:
